U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Lung Squamous Cell Carcinoma

MedGen UID:
1756132
•Concept ID:
C5420147
•
Neoplastic Process

Definition

Lung squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Lung Squamous Cell Carcinoma

Professional guidelines

PubMed

EGFR L861Q and CDK4 amplification responding to afatinib combined with palbociclib treatment in a patient with advanced lung squamous cell carcinoma.
Jiang H, Luo N, Zhang X, Song C, Zang J
Lung Cancer 2020 Jul;145:216-218. Epub 2020 Apr 15 doi: 10.1016/j.lungcan.2020.04.001. PMID: 32345450
Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma.
Zeng DX, Lei W, Wang CG, Huang JA, Jiang JH
Cancer Chemother Pharmacol 2019 Mar;83(3):439-442. Epub 2018 Dec 13 doi: 10.1007/s00280-018-3743-0. PMID: 30547193
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma.
Si X, Wu S, Wang H, Zhang X, Wang M, Zeng X, Zhang L
Thorac Cancer 2018 Aug;9(8):1056-1061. Epub 2018 Jun 19 doi: 10.1111/1759-7714.12789. PMID: 29920955Free PMC Article

Recent clinical studies

Etiology

Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
Zheng X, Zhang L, Wu L, Zhao J, Sun J, Fang Y, Zhou J, Chu Q, Shen Y, Yang Z, Chen L, Huang M, Lin X, Liu Z, Shen P, Wang Z, Wang X, Wang H, Han Z, Liu A, Zhang H, Ye F, Gao W, Wu F, Song Z, Chen S, Zhou C, Wang Q, Xu C, Huang D, Zheng X, Miao Q, Jiang K, Xu Y, Wu S, Wang H, Zhang Q, Yang S, Li Y, Chen S, Lin G
BMC Cancer 2023 Dec 16;23(1):1244. doi: 10.1186/s12885-023-11737-x. PMID: 38104105Free PMC Article
Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis.
Qin J, Yi S, Zhou H, Zeng C, Zou M, Zeng X, Yang Z, Huang Y
Front Immunol 2023;14:1138025. Epub 2023 May 16 doi: 10.3389/fimmu.2023.1138025. PMID: 37261356Free PMC Article
Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.
Kinoshita F, Oku Y, Takamori S, Fujishita T, Toyozawa R, Ito K, Shoji F, Okamoto T
Invest New Drugs 2023 Feb;41(1):168-172. Epub 2022 Nov 4 doi: 10.1007/s10637-022-01312-9. PMID: 36331673
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Jiang T, Chen J, Xu X, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Zhang Y, Zhang J, Yang Z, Shi W, Zou J, Zhou C, Ren S
Mol Cancer 2022 Jan 3;21(1):4. doi: 10.1186/s12943-021-01479-4. PMID: 34980131Free PMC Article
Efficacy of icotinib in advanced lung squamous cell carcinoma.
Liang S, Xu Y, Tan F, Ding L, Ma Y, Wang M
Cancer Med 2018 Sep;7(9):4456-4466. Epub 2018 Aug 14 doi: 10.1002/cam4.1736. PMID: 30109777Free PMC Article

Diagnosis

Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.
Kinoshita F, Oku Y, Takamori S, Fujishita T, Toyozawa R, Ito K, Shoji F, Okamoto T
Invest New Drugs 2023 Feb;41(1):168-172. Epub 2022 Nov 4 doi: 10.1007/s10637-022-01312-9. PMID: 36331673
Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma.
Guo Q, Wu CY, Jiang N, Tong S, Wan JH, Xiao XY, Mei PY, Liu HS, Wang SH
Front Immunol 2022;13:986447. Epub 2022 Dec 5 doi: 10.3389/fimmu.2022.986447. PMID: 36544782Free PMC Article
A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F, Xu Y, Guo S, Li S, Ma K, Wang J, Wei S
Ann Palliat Med 2022 Sep;11(9):3020-3027. doi: 10.21037/apm-22-960. PMID: 36217630
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Jiang T, Chen J, Xu X, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Zhang Y, Zhang J, Yang Z, Shi W, Zou J, Zhou C, Ren S
Mol Cancer 2022 Jan 3;21(1):4. doi: 10.1186/s12943-021-01479-4. PMID: 34980131Free PMC Article
Erlotinib in patients with advanced lung squamous cell carcinoma.
Chiang CL, Tsai CM, Chou TY, Chen YM, Lai SL, Shih JF, Chiu CH, Lee YC
Cancer Chemother Pharmacol 2013 Jan;71(1):203-8. Epub 2012 Oct 10 doi: 10.1007/s00280-012-1997-5. PMID: 23053274

Therapy

Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.
Duan J, Zhang Y, Chen R, Liang L, Huo Y, Lu S, Zhao J, Hu C, Sun Y, Yang K, Chen M, Yu Y, Ying J, Huang R, Ma X, Leaw S, Bai F, Shen Z, Cai S, Gao D, Wang J, Wang Z
Cell Rep Med 2023 Dec 19;4(12):101302. Epub 2023 Dec 4 doi: 10.1016/j.xcrm.2023.101302. PMID: 38052215Free PMC Article
Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.
Kinoshita F, Oku Y, Takamori S, Fujishita T, Toyozawa R, Ito K, Shoji F, Okamoto T
Invest New Drugs 2023 Feb;41(1):168-172. Epub 2022 Nov 4 doi: 10.1007/s10637-022-01312-9. PMID: 36331673
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Jiang T, Chen J, Xu X, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Zhang Y, Zhang J, Yang Z, Shi W, Zou J, Zhou C, Ren S
Mol Cancer 2022 Jan 3;21(1):4. doi: 10.1186/s12943-021-01479-4. PMID: 34980131Free PMC Article
The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
Yuan H, Liu J, Zhang J
Molecules 2021 Mar 5;26(5) doi: 10.3390/molecules26051392. PMID: 33807509Free PMC Article
Efficacy of icotinib in advanced lung squamous cell carcinoma.
Liang S, Xu Y, Tan F, Ding L, Ma Y, Wang M
Cancer Med 2018 Sep;7(9):4456-4466. Epub 2018 Aug 14 doi: 10.1002/cam4.1736. PMID: 30109777Free PMC Article

Prognosis

Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
Zheng X, Zhang L, Wu L, Zhao J, Sun J, Fang Y, Zhou J, Chu Q, Shen Y, Yang Z, Chen L, Huang M, Lin X, Liu Z, Shen P, Wang Z, Wang X, Wang H, Han Z, Liu A, Zhang H, Ye F, Gao W, Wu F, Song Z, Chen S, Zhou C, Wang Q, Xu C, Huang D, Zheng X, Miao Q, Jiang K, Xu Y, Wu S, Wang H, Zhang Q, Yang S, Li Y, Chen S, Lin G
BMC Cancer 2023 Dec 16;23(1):1244. doi: 10.1186/s12885-023-11737-x. PMID: 38104105Free PMC Article
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.
Duan J, Zhang Y, Chen R, Liang L, Huo Y, Lu S, Zhao J, Hu C, Sun Y, Yang K, Chen M, Yu Y, Ying J, Huang R, Ma X, Leaw S, Bai F, Shen Z, Cai S, Gao D, Wang J, Wang Z
Cell Rep Med 2023 Dec 19;4(12):101302. Epub 2023 Dec 4 doi: 10.1016/j.xcrm.2023.101302. PMID: 38052215Free PMC Article
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Jiang T, Chen J, Xu X, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Zhang Y, Zhang J, Yang Z, Shi W, Zou J, Zhou C, Ren S
Mol Cancer 2022 Jan 3;21(1):4. doi: 10.1186/s12943-021-01479-4. PMID: 34980131Free PMC Article
The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
Yuan H, Liu J, Zhang J
Molecules 2021 Mar 5;26(5) doi: 10.3390/molecules26051392. PMID: 33807509Free PMC Article
Erlotinib in patients with advanced lung squamous cell carcinoma.
Chiang CL, Tsai CM, Chou TY, Chen YM, Lai SL, Shih JF, Chiu CH, Lee YC
Cancer Chemother Pharmacol 2013 Jan;71(1):203-8. Epub 2012 Oct 10 doi: 10.1007/s00280-012-1997-5. PMID: 23053274

Clinical prediction guides

Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.
Duan J, Zhang Y, Chen R, Liang L, Huo Y, Lu S, Zhao J, Hu C, Sun Y, Yang K, Chen M, Yu Y, Ying J, Huang R, Ma X, Leaw S, Bai F, Shen Z, Cai S, Gao D, Wang J, Wang Z
Cell Rep Med 2023 Dec 19;4(12):101302. Epub 2023 Dec 4 doi: 10.1016/j.xcrm.2023.101302. PMID: 38052215Free PMC Article
Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.
Kinoshita F, Oku Y, Takamori S, Fujishita T, Toyozawa R, Ito K, Shoji F, Okamoto T
Invest New Drugs 2023 Feb;41(1):168-172. Epub 2022 Nov 4 doi: 10.1007/s10637-022-01312-9. PMID: 36331673
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Jiang T, Chen J, Xu X, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Zhang Y, Zhang J, Yang Z, Shi W, Zou J, Zhou C, Ren S
Mol Cancer 2022 Jan 3;21(1):4. doi: 10.1186/s12943-021-01479-4. PMID: 34980131Free PMC Article
The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
Yuan H, Liu J, Zhang J
Molecules 2021 Mar 5;26(5) doi: 10.3390/molecules26051392. PMID: 33807509Free PMC Article
Efficacy of icotinib in advanced lung squamous cell carcinoma.
Liang S, Xu Y, Tan F, Ding L, Ma Y, Wang M
Cancer Med 2018 Sep;7(9):4456-4466. Epub 2018 Aug 14 doi: 10.1002/cam4.1736. PMID: 30109777Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...